Miliary tuberculosis developing during adalimumab treatment for Behçet’s disease with uveitis

Tumour necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine in non-infective uveitis (NIU). Adalimumab, an anti-TNF-α monoclonal antibody, is approved for the treatment of severe NIU by the European Medicines Agency. There is a recognised risk of serious infections, including tuberculosis...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMJ Case Rep
Auteurs principaux: Kim, Minji Jennifer, Jones, Nicholas, Steeples, Laura R
Format: Artigo
Langue:Inglês
Publié: BMJ Publishing Group 2018
Sujets:
Findings That Shed New Light on the Possible Pathogenesis of a Disease or an Adverse Effect
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6301654/
https://ncbi.nlm.nih.gov/pubmed/30567192
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2018-226772
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires